PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
AKRO vs. AVGO
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

AKRO vs. AVGO

Last updated Apr 2, 2026

Compare and contrast key facts about Akero Therapeutics, Inc. (AKRO) and Broadcom Inc. (AVGO).

Performance

AKRO vs. AVGO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Akero Therapeutics, Inc. (AKRO) and Broadcom Inc. (AVGO). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

AKRO vs. AVGO - Yearly Performance Comparison

2026 (YTD)2025202420232022202120202019
AKRO
Akero Therapeutics, Inc.		0.00%96.44%19.14%-57.39%159.10%-18.02%16.24%21.15%
AVGO
Broadcom Inc.		-9.23%50.63%110.49%104.18%-13.27%56.48%44.88%16.56%

Fundamentals

Market Cap

AKRO:

$4.48B

AVGO:

$1.53T

EPS

AKRO:

-$3.58

AVGO:

$5.13

PB Ratio

AKRO:

4.68

AVGO:

19.18

Total Revenue (TTM)

AKRO:

$0.00

AVGO:

$68.28B

Gross Profit (TTM)

AKRO:

$0.00

AVGO:

$46.31B

EBITDA (TTM)

AKRO:

-$288.18M

AVGO:

$36.65B

Returns By Period

AKRO

1D
—
1M
—
YTD
—
6M
—
1Y
—
3Y*
—
5Y*
—
10Y*
—

AVGO

1D
1.29%
1M
-1.47%
YTD
-9.23%
6M
-5.59%
1Y
87.53%
3Y*
71.96%
5Y*
48.74%
10Y*
38.30%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Akero Therapeutics, Inc.

Broadcom Inc.

Often compared with AKRO:
AKRO vs. SPYAKRO vs. GDEAKRO vs. QQQAKRO vs. CRVS
Often compared with AVGO:
AVGO vs. NVDAAVGO vs. MRVLAVGO vs. QCOMAVGO vs. VOOAVGO vs. ^GSPCAVGO vs. AAPLAVGO vs. SCHD

Return for Risk

AKRO vs. AVGO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
AKRO
AVGO
AVGO Risk / Return Rank: 8686
Overall Rank
AVGO Sharpe Ratio Rank: 8888
Sharpe Ratio Rank
AVGO Sortino Ratio Rank: 8686
Sortino Ratio Rank
AVGO Omega Ratio Rank: 8484
Omega Ratio Rank
AVGO Calmar Ratio Rank: 8686
Calmar Ratio Rank
AVGO Martin Ratio Rank: 8484
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AKRO vs. AVGO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Akero Therapeutics, Inc. (AKRO) and Broadcom Inc. (AVGO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

AKRO vs. AVGO - Sharpe Ratio Comparison

Loading graphics...

Sharpe Ratios by Period

AKROAVGODifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

—

1.82

—

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

—

1.16

—

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

—

0.99

—

Sharpe Ratio (All Time)

Calculated using the full available price history

—

1.06

—

Correlation

The correlation between AKRO and AVGO is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AKRO vs. AVGO - Dividend Comparison

AKRO has not paid dividends to shareholders, while AVGO's dividend yield for the trailing twelve months is around 0.79%.

TTM20252024202320222021202020192018201720162015
AKRO
Akero Therapeutics, Inc.		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
AVGO
Broadcom Inc.		0.79%0.70%0.94%1.71%3.02%2.24%3.05%3.54%3.11%1.87%1.43%1.13%

Drawdowns

AKRO vs. AVGO - Drawdown Comparison

Loading graphics...

Drawdown Indicators

AKROAVGODifference

Max Drawdown

Largest peak-to-trough decline

—

-48.30%

—

Max Drawdown (1Y)

Largest decline over 1 year

—

-28.67%

—

Max Drawdown (5Y)

Largest decline over 5 years

—

-41.15%

—

Max Drawdown (10Y)

Largest decline over 10 years

—

-48.30%

—

Current Drawdown

Current decline from peak

—

-23.78%

—

Average Drawdown

Average peak-to-trough decline

—

-8.00%

—

Ulcer Index

Depth and duration of drawdowns from previous peaks

—

11.66%

—

Volatility

AKRO vs. AVGO - Volatility Comparison

Loading graphics...

Volatility by Period

AKROAVGODifference

Volatility (1M)

Calculated over the trailing 1-month period

—

12.62%

—

Volatility (6M)

Calculated over the trailing 6-month period

—

32.50%

—

Volatility (1Y)

Calculated over the trailing 1-year period

—

48.25%

—

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

—

42.33%

—

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

—

38.90%

—

Financials

AKRO vs. AVGO - Financials Comparison

This section allows you to compare key financial metrics between Akero Therapeutics, Inc. and Broadcom Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

0.005.00B10.00B15.00B20.00BAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
19.31B
(AKRO) Total Revenue
(AVGO) Total Revenue
Values in USD except per share items